Skip to main content

Advertisement

SpringerLink
Log in

Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objectives

To understand change in work productivity, activity impairment, quality of life (QoL), and disease activity in patients with psoriatic arthritis (PsA) receiving anti-tumor necrosis factor (anti-TNF) treatment.

Method

One hundred twenty patients with PsA receiving anti-TNF therapy were recruited to this noninterventional, observational study. Work disability was assessed via the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity was calculated via the 28-joint Disease Activity Score using C-reactive protein (DAS28-CRP) and Disease Activity Index for Psoriatic Arthritis with 28 joints (DAPSA28) score. Patient-reported outcomes (PROs), from visual analog scores and Health Assessment Questionnaire-Disability Index scores, were evaluated to understand the clinical effectiveness at baseline and every 3 months until the month-9 final visit. The American College of Rheumatology (ACR)20/50/70 response criteria were assessed at month 9.

Results

A total of 120 patients (females, n = 73) were enrolled in the study. Mean (SD) age and disease duration were 41.6 ± 11.1 years and 6.9 ± 6.5 years, respectively. The most commonly used TNFα inhibitor was adalimumab (42.4%), followed by etanercept (25.8%). All WPAI questionnaire parameters were reduced at the follow-up visits compared with baseline (p < 0.001 for all). PROs and disease activity indicators (DAS28-CRP and DAPSA28) significantly improved during the course of anti-TNF treatments (p < 0.001 for all). Additionally, ACR20/50/70 responses were determined as 86.8%, 63.7%, and 41.8% of patients at the month-9 visit.

Conclusions

The real-world data in PsA patients receiving anti-TNF treatment showed improvement in WPAI, QoL, and disease activity over 9 months of treatment.

Trial registration

NCT02028169

Key Points

• Psoriatic arthritis (PsA), with debilitating effects on quality of life, occurs mostly in young adults and has negative impacts on employment status and work productivity.

• Early PsA diagnosis and treat-to-target treatment strategies aim to reduce pain and joint damage, as well as improve work productivity.

• Real-world data on the impact of treatment with anti-tumor necrosis factor (anti-TNF) agents on work productivity in PsA in the literature is scarce.

• Our study of real-world data in patients with PsA receiving anti-TNF treatment showed improvement in work productivity, as well as in clinical and patient-reported outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Data are available upon reasonable request.

Code availability

Not applicable.

References

  1. Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957–970. https://doi.org/10.1056/NEJMra1505557

    Article  PubMed  Google Scholar 

  2. Tucker LJ, Coates LC, Helliwell PS (2019) Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther 6(1):23–32. https://doi.org/10.1007/s40744-018-0132-4

    Article  PubMed  Google Scholar 

  3. Lubrano E, Scriffignano S, Perrotta FM (2019) TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Rev Clin Immunol 15(12):1303–1312. https://doi.org/10.1080/1744666x.2020.1685382

    Article  PubMed  CAS  Google Scholar 

  4. Pukšić S, Bolton-King P, Sexton J, Michelsen B, Kvien TK, Berner Hammer H (2018) DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs. RMD Open 4(2):e000765. https://doi.org/10.1136/rmdopen-2018-000765

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bagel J, Schwartzman S (2018) Enthesitis and dactylitis in psoriatic disease: a guide for dermatologists. Am J Clin Dermatol 19(6):839–852. https://doi.org/10.1007/s40257-018-0377-2

    Article  PubMed  PubMed Central  Google Scholar 

  6. Tillett W, Shaddick G, Jobling A, Askari A, Cooper A, Creamer P, Clunie G, Helliwell PS, James J, Kay L, Korendowych E, Lane S, Packham J, Shaban R, Thomas ML, Williamson L, McHugh N (2017) Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology (Oxford) 56(4):603–612. https://doi.org/10.1093/rheumatology/kew433

    Article  Google Scholar 

  7. Palsson O, Love TJ, Gunnarsdottir AI, Gunnarsson PS, Runarsdottir EE, Krogh NS, Gudbjornsson B (2019) Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible. RMD Open 5(2):e000984. https://doi.org/10.1136/rmdopen-2019-000984

    Article  PubMed  PubMed Central  Google Scholar 

  8. Tsuruta N, Narisawa Y, Imafuku S, Ito K, Yamaguchi K, Miyagi T, Takahashi K, Fukamatsu H, Morizane S, Koketsu H, Yamaguchi M, Hino R, Nakamura M, Ohyama B, Ohata C, Kuwashiro M, Sato T, Saito K, Kaneko S, Yonekura K, Hayashi H, Yanase T, Morimoto K, Sugita K, Yanagihara S, Kikuchi S, Mitoma C, Nakahara T, Furue M, Okazaki F (2019) Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-α inhibitors. J Dermatol 46(3):193–198. https://doi.org/10.1111/1346-8138.14745

    Article  PubMed  CAS  Google Scholar 

  9. van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh AF (2018) Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. RMD Open 4(1):e000659. https://doi.org/10.1136/rmdopen-2018-000659

    Article  PubMed  PubMed Central  Google Scholar 

  10. Black CM (2012) Sickness absence and musculoskeletal disorders. Rheumatology (Oxford) 51(2):204–205. https://doi.org/10.1093/rheumatology/ker323

    Article  Google Scholar 

  11. Short P, Jones AC, Walker D, Kavanaugh A, Moots RJ (2012) Working at arthritis. Rheumatology (Oxford) 51(2):201–203. https://doi.org/10.1093/rheumatology/ker415

    Article  Google Scholar 

  12. Beaton DE, Dyer S, Boonen A, Verstappen SM, Escorpizo R, Lacaille DV, Bosworth A, Gignac MA, Leong A, Purcaru O, Leggett S, Hofstetter C, Peterson IF, Tang K, Fautrel B, Bombardier C, Tugwell PS (2016) OMERACT filter evidence supporting the measurement of at-work productivity loss as an outcome measure in rheumatology research. J Rheumatol 43(1):214–222. https://doi.org/10.3899/jrheum.141077

    Article  PubMed  Google Scholar 

  13. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewé RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Rodrigues Manica SA, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700–712. https://doi.org/10.1136/annrheumdis-2020-217159

    Article  PubMed  Google Scholar 

  14. Fransen J, van Riel PL (2009) The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 35(4):745-757 vii-viii. https://doi.org/10.1016/j.rdc.2009.10.001

    Article  PubMed  Google Scholar 

  15. Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML (2018) Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? Ann Rheum Dis 77(12):1736–1741. https://doi.org/10.1136/annrheumdis-2018-213463

    Article  PubMed  CAS  Google Scholar 

  16. Kalyoncu U BO, Oksuz MF, Kimyon G, Erden A, Yavuz S, Cetin G, Kucuksahin O, Kilic L, Omma A, Ozisler C, Solmaz D, Onat AM, Kisacik B, Ersozlu Bakirli D, Cinar M, Tufan A, Yildiz F, Mercan R, Kasifoglu T, Yilmazer B, Yilmaz S, Aksu K, Erten S, Sayarlioglu M, Dalkilic E, Akar S, Acikel C, Aydin Tufan M, Balkarli A, Kasapoglu-Gunal E, Senel S, Kobak S, Duruoz MT, Dogru A, Tarhan EF, Can M, Akyol L, Pehlevan S, Erbasan F, Arslan F, Kucuk A, Gonullu E, Kabasakal Y, Sahin M, Atakan N, Aydin SZ (2016) Dapsa-28 may be used instead of Dapsa-66/68 in psoriatic arthritis [abstract]. Arthritis Rheumatol 68(10):3689–3690. https://acrabstracts.org/abstract/dapsa-28-may-be-used-instead-of-dapsa-6668-in-psoriatic-arthritis/

  17. Lee MP, Lii J, Jin Y, Desai RJ, Solomon DH, Merola JF, Kim SC (2018) Patterns of systemic treatment for psoriatic arthritis in the US: 2004–2015. Arthritis Care Res (Hoboken) 70(5):791–796. https://doi.org/10.1002/acr.23337

    Article  Google Scholar 

  18. Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 43(2):350–355. https://doi.org/10.3899/jrheum.150805

    Article  PubMed  CAS  Google Scholar 

  19. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673. https://doi.org/10.1002/art.21972

    Article  PubMed  Google Scholar 

  20. Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353–365. https://doi.org/10.2165/00019053-199304050-00006

    Article  PubMed  CAS  Google Scholar 

  21. Klaudius I, Krueger K, Remstedt S, Thiele A (2018) SAT0187 Golimumab improves work productivity and activity impairment in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PSA): 1-year results from a non- interventional trial in Germany. Ann Rheum Dis 77(Suppl 2):954–955. https://doi.org/10.1136/annrheumdis-2018-eular.2925

    Article  Google Scholar 

  22. Mease P (2020) Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management. Rheumatology (Oxford) 59(Supplement_1):i21–i28. https://doi.org/10.1093/rheumatology/keaa042

    Article  Google Scholar 

  23. Kavanaugh A, Mease P (2012) Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). J Rheumatol Suppl 89:90–93. https://doi.org/10.3899/jrheum.120254

    Article  PubMed  CAS  Google Scholar 

  24. Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75(5):811–818. https://doi.org/10.1136/annrheumdis-2015-207507

    Article  PubMed  Google Scholar 

  25. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64(8):1150–1157. https://doi.org/10.1136/ard.2004.032268

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68(5):702–709. https://doi.org/10.1136/ard.2008.092767

    Article  PubMed  CAS  Google Scholar 

  27. Gladman DD, Sampalis JS, Illouz O, Guérette B (2010) Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 37(9):1898–1906. https://doi.org/10.3899/jrheum.100069

    Article  PubMed  Google Scholar 

  28. Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P (2013) Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 65(10):1666–1673. https://doi.org/10.1002/acr.22044

    Article  CAS  Google Scholar 

  29. Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ (2014) Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res (Hoboken) 66(7):1085–1092. https://doi.org/10.1002/acr.22256

    Article  CAS  Google Scholar 

  30. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227–1236. https://doi.org/10.1002/art.20967

    Article  PubMed  CAS  Google Scholar 

  31. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66(4):498–505. https://doi.org/10.1136/ard.2006.058339

    Article  PubMed  CAS  Google Scholar 

  32. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227):385–390. https://doi.org/10.1016/s0140-6736(00)02530-7

    Article  PubMed  CAS  Google Scholar 

  33. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60(4):976–986. https://doi.org/10.1002/art.24403

    Article  PubMed  CAS  Google Scholar 

  34. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73(1):48–55. https://doi.org/10.1136/annrheumdis-2013-203696

    Article  PubMed  CAS  Google Scholar 

  35. Damjanov N, Karpati S, Kemeny L, Bakos N, Bobic B, Majdan M, Tlustochowicz W, Vitek P, Dokoupilova E, Aldinc E, Szumski A (2018) Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe. J Dermatolog Treat 29(1):8–12. https://doi.org/10.1080/09546634.2017.1329509

    Article  PubMed  CAS  Google Scholar 

  36. Kalyoncu U, Bayindir Ö, Ferhat Öksüz M, Doğru A, Kimyon G, Tarhan EF, Erden A, Yavuz Ş, Can M, Çetin GY, Kılıç L, Küçükşahin O, Omma A, Ozisler C, Solmaz D, Bozkirli ED, Akyol L, Pehlevan SM, Gunal EK, Arslan F, Yılmazer B, Atakan N, Aydın SZ (2017) The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford) 56(2):279–286. https://doi.org/10.1093/rheumatology/kew375

    Article  Google Scholar 

  37. Bhutani T, Wong JW, Bebo BF, Armstrong AW (2013) Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol 149(6):717–721. https://doi.org/10.1001/jamadermatol.2013.133

    Article  PubMed  Google Scholar 

  38. Ayan G, Aydin SZ, Kimyon G, Ozisler C, Tinazzi I, Dogru A, Omma A, Kilic L, Yılmaz S, Kucuksahin O, Gönüllü E, Yıldız F, Can M, Balkarlı A, Solmaz D, Dalkılıc E, Bayindir O, Yıldırım Çetin G, Ergulu Esmen S, Ersozlu ED, Duruoz MT, Akyol L, Kucuk A, Bes C, Cınar M, Erden A, Mercan R, Bakirci S, Kasifoglu T, Yazısız V, Kalyoncu U (2021) PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. Rheumatology (Oxford) 60(4):1755–1762. https://doi.org/10.1093/rheumatology/keaa663

    Article  Google Scholar 

Download references

Acknowledgements

Servet Yolbas, MD, (Inonu University—Turgut Ozal School of Medicine, Department of Internal Medicine, Division of Rheumatology, Malatya—Turkey) and Gokhan Temiz, MD, (Atasehir Memorial Hospital—Nephrology Clinic, Istanbul—Turkey) served as subinvestigators in this study. Murat Ozdemir and Monitor CRO provided medical writing, editing, and reviewing services support in the development of this manuscript, which was funded by AbbVie.

Funding

AbbVie sponsored the study; contributed to the design; and participated in the collection, analysis, and interpretation of data; and in writing, reviewing, and approval of the final version. No honoraria or payments were made for authorship.

Author information

Authors and Affiliations

  1. School of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey

    Omer Karadag, Gizem Ayan & Umut Kalyoncu

  2. School of Medicine, Department of Internal Medicine, Division of Rheumatology, Uludag University, Bursa, Turkey

    Ediz Dalkilic

  3. Ankara City Hospital – School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara Yildirim Beyazit University, Ankara, Turkey

    Orhan Kucuksahin & Sukran Erten

  4. School of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University, Eskisehir, Turkey

    Timucin Kasifoglu

  5. Istanbul Florence Nightingale Hospital, Department of Rheumatology, Demiroglu Bilim University, Istanbul, Turkey

    Neslihan Yilmaz

  6. School of Medicine, Department of Internal Medicine, Division of Rheumatology, Firat University, Elazig, Turkey

    Suleyman Serdar Koca

  7. School of Medicine, Department of Internal Medicine, Division of Rheumatology, Akdeniz University, Antalya, Turkey

    Veli Yazisiz & Mustafa Ender Terzioglu

  8. Medical Park, Department of Internal Medicine, Division of Rheumatology, Izmir Economy University, Izmir, Turkey

    Pinar Talu Erten

  9. Department of Internal Medicine, Division of Rheumatology, Liv Hospital Samsun, Samsun, Turkey

    Mehmet Sayarlioglu

Authors
  1. Omer Karadag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ediz Dalkilic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gizem Ayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Orhan Kucuksahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Timucin Kasifoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Neslihan Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Suleyman Serdar Koca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Veli Yazisiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pinar Talu Erten
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mehmet Sayarlioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mustafa Ender Terzioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Sukran Erten
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Umut Kalyoncu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to conduction and writing of this study and have approved the final version.

Corresponding author

Correspondence to Omer Karadag.

Ethics declarations

Ethics approval

This study was approved by the Clinical Research Ethics Committee of Hacettepe University on October 31, 2013, with an approval number: 2013/13–03 (KA-130083).

Consent to participate

Written informed consent was received before enrolment from all participants.

Consent to publication

Not applicable.

Conflict of interest

Omer Karadag: AbbVie (research grant, consulting fee), Pfizer (research grant, consulting fee), Roche (research grant, consulting fee), Novartis (research grant), Abdi İbrahim (consulting fee), Amgen (consulting fee), Farmanova (consulting fee), Janssen (consulting fee), Lilly (consulting fee), UCB (consulting fee). Ediz Dalkilic: AbbVie (speaker fee), MSD (speaker fee), Roche (speaker fee), Pfizer (speaker fee), UCB (speaker fee), Novartis (speaker fee). Gizem Ayan: None. Orhan Kucuksahin: None. Timucin Kasifoglu: AbbVie, Amgen, Roche, MSD, Novartis, Pfizer, and UCB (speaker and consulting fees). Neslihan Yilmaz: AbbVie (speaker fee), Pfizer (speaker fee), UCB (speaker fee), Roche (speaker fee), Janssen (speaker fee). Suleyman Serdar Koca: AbbVie (speaker fee), Pfizer (speaker fee), Roche (speaker fee), UCB (speaker fee), Novartis (speaker fee), Amgen (speaker fee), Pharmactive (speaker fee), MSD (speaker fee). Veli Yazisiz: AbbVie (consulting fee), Pfizer (consulting fee), UCB (consulting fee). Pinar Talu Erten: None. Mehmet Sayarlioglu: Genzyme (speaker fee), MSD (consulting fee), Novartis (research grant). Mehmet Ender Terzioglu: AbbVie, Pfizer, Novartis, Boehringer Ingelheim, Pharmactive, and UCB (speaker/consulting fee and/or research grant). Sukran Erten: Janssen (speaker fee), Roche (speaker fee), Novartis (speaker fee). Umut Kalyoncu: AbbVie, Pfizer (research grant, speaker, and consulting fee), Janssen (research grant, speaker fee), UCB, Novartis (speaker and consulting fee), Lilly (consulting fee).

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karadag, O., Dalkilic, E., Ayan, G. et al. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Clin Rheumatol 41, 85–94 (2022). https://doi.org/10.1007/s10067-021-05893-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-021-05893-3

Keywords

Search

Navigation